Colorectal cancer screening is an effective tool for catching the disease early when it’s most treatable, yet it is underutilized in patient populations who receive primary care at federally qualified health centers.
Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity.
